For current stage of knowledge see reference 1. 118220, 118210, 118200, 609260, 162500, 145900, 302800 607677, 605253, 256850, 162100, 601455, 608323 and 607736. 1.3 Name of the analysed genes or DNA/chromosome segments PMP22, MPZ, GJB1 (CX32), MFN2, EGR2, SIMPLE, NEFL, DNM2, RAB7, SH3TC2, GDAP1, GARS, PRX, LMNA, BSCL2, CTDP1, FIG4, MTMR2, SBF2/MTMR13, FGD4, NDRG1, YARS, AlaRS and SEPT9. Current stage of knowledge, annual revision recommended. 601097, 159440, 304040, 608507, 129010, 603795, 162280, 602378, 602298, 608206, 606598, 600287, 605725, 150330, 606158, 604927,609390, 603557, 607697, 605379, 611104, and 604061 . Current state of knowledge, annual revision recommended.
OMIM# of the disease

OMIM# of the gene(s)
1.5 Mutational spectrum 30-50% CMT1A duplication/HNPP deletion in chromosome region 17p11.2 (PMP22).
Remaining patients: private and recurrent mutations in any of the above-mentioned and newly identified genes (see reference 2).
1.6 Analytical methods MLPA, Mulitplex Amplicon Quantification (MAQ) (http://www. vibgeneticservicefacility.be/tech/MAQ_Application_Note_1.1.pdf), microsatellite analysis, qPCR, Southern blot, FISH for PMP22 duplication/deletion screening, PFGE, dHPLC, high-resolution melting, restriction analysis, direct sequencing (current state of knowledge).
Analytical validation
Participation on proficiency tests. For detection of the CMT1A duplication/HNPP deletion two methods are used, and the results of which verify each other. The results of the molecular genetic diagnostics are unambiguously evaluated, as a rule.
1.8 Estimated frequency of the disease (incidence at birth ('birth prevalence') or population prevalence) Prevalence in the general population 10-40 per 100 000, in Finland 1:2500. 
Diagnostic setting
Comment:
A prenatal test is rarely requested. 
TEST CHARACTERISTICS
Clinical specificity (proportion of negative tests if the disease is not present)
The clinical specificity can be dependent on variable factors such as age or family history. In such cases a general statement should be given, even if a quantification can only be made case by case. Almost 100%.
Positive clinical predictive value (lifetime risk to develop the disease if the test is positive)
The penetrance in verified mutation carriers is almost 100%, according to the literature; because of the wide clinical variability, clinically mildly affected persons may not be diagnosed or they died from other causes in the preclinical stage.
2.6 Negative clinical predictive value (probability not to develop the disease if the test is negative) Assume an increased risk based on family history for a non-affected person. Allelic and locus heterogeneity may need to be considered.
Index case in that family had been tested: Almost 100%. Index case in that family had not been tested:
About 86% (detection rate of mutations). As a rule, however, such an approach is not recommended. 3.4 Prenatal diagnosis (To be answered if in 1.10 'D' was marked) 3.4.1 Does a positive genetic test result in the index patient enable a prenatal diagnostic? Yes, but is rarely requested.
CLINICAL UTILITY
IF APPLICABLE, FURTHER CONSEQUENCES OF TESTING
Please assume that the result of a genetic test has no immediate medical consequences. Is there any evidence that a genetic test is nevertheless useful for the patient or his/her relatives? (Please describe).
Verification of the diagnosis is for many patients a value in itself, irrespective of medical benefits: it gives the disease a name and often explains their cause.
Demonstration of a genetic cause eliminates the feeling of guilt and 'own faults' (exogenous poisons, 'incorrect conduct'), which may be relieving.
Knowledge of the individual mutation may enable in the future the access to therapies that are presently in developmental stage. Effects of neurotoxic compounds, eg chemotherapeutic agents for treatment of cancer, can be ameliorated or avoided.
